Histologic diagnosis of pancreatic masses using 22-gauge endoscopic ultrasound needles with and without franseen design :A multicenter randomized controlled trial

Histologic diagnosis of pancreatic masses using 22-gauge endoscopic ultrasound needles with and without franseen design :A multicenter randomized controlled trial - A multicenter randomized controlled trial for Endoscopic ultrasound-guided fine needle aspiration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030634

Enrollment

520

Registered

2018-04-01

Start date

2018-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic mass

Interventions

EUS-FNA using 22-gauge standard needle EUS-FNA using 22-gauge franseen needle

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: # patients with pancreatic mass detected by imaging # Performace status 1 or 2 # Case that need a histologic diagnosis for the choice of the therapeutic method # Written informed consent

Exclusion criteria

Exclusion criteria: # Inability to perform EUS-FNA # Case with the bleeding tendency # Inability to perform endoscopy # Inabiltity to depict pancreatic mass by EUS # Serious failure of other organs # Case judged to be inadequate for this study

Design outcomes

Primary

Measure	Time frame
Accuracy for histrogical diagnosis	—

Countries

Japan

Contacts

Public ContactMasahiro Itonaga

Wakayama medical university Second Department of Internal Medicine

itonaga@wakayama-med.ac.jp073-447-2300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026